Derivatives of rupestonic acid (5a–e) were synthesized and evaluated preliminarily at the National Center for Drug Screening (PRC) for antiviral activity against type A3 and B flu virus and HSV-I and HSV-II in order to improve the biological activity of rupestonic acid. It was found that compound 5b was more active than rupestonic acid against type A3 flu virus.
为了提高鲁帕斯顿酸的
生物活性,我们合成了鲁帕斯顿酸的衍
生物(5a-e),并在国家新药筛选中心(中国)对其抗 A3 型和 B 型流感病毒、抗 HSV-I 型和 HSV-II 型病毒的活性进行了初步评价。结果发现,化合物 5b 对 A3 型流感病毒的活性高于芦贝特酸。